Eli Lilly and Company (NYSE:LLY) is one of the top S&P 500 stocks by index weight. On April 15, BMO Capital reiterated an ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the ...

Parkland School Board members expressed deep skepticism about a proposed tax break for Eli Lilly, using their Tuesday ...

Eli Lilly (NYSE:LLY) has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal brings ...

On April 15, 2026, Eli Lilly and Company (NYSE:LLY) reported topline results from the Phase 3 ACHIEVE-4 trial evaluating ...

Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026.

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

Pharma giant Eli Lilly and Co. is on a multibillion-dollar Boston buying spree. Its latest acquisition: a gene therapy ...

Eli Lilly is in talks to buy Kelonia Therapeutics for $2B+, boosting its oncology pipeline with next-gen CAR-T for multiple ...

A federal judge ruled Eli Lilly & Co. can proceed with its lawsuit against a business selling copycat versions of its obesity ...

Eli Lilly has another promising drug in its portfolio with Foundayo. Its growth rate has been more than 40% in recent ...